Download PDFPDF
Research paper
Cerebral amyloid angiopathy related inflammation: three case reports and a review
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

  • Published on:
    Re:Anti-A? autoantibodies in cerebral amyloid angiopathy related inflammation: a role for pathogenesis?
    • P. Alan Barber, Professor of Clinical Neurology
    • Other Contributors:
      • Kong Khi Chung, Neil E. Anderson, David Hutchinson, Beth Synek

    We thank Drs DiFrancesco et al for their comments on our recent paper in which we proposed diagnostic criteria for cerebral amyloid related inflammation (CAA-I). The report by this group of an increase in anti- amyloid beta autoantibodies in a 68 year old man with probable CAA-I is of interest and may well help further our understanding of the pathogenesis of CAA-I. However, we agree that this finding must be confirmed in a...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Anti-A? autoantibodies in cerebral amyloid angiopathy related inflammation: a role for pathogenesis?
    • Jacopo C. DiFrancesco, MD, PhD
    • Other Contributors:
      • Fabrizio Piazza,2 Elisa Conti,2 Lucio Tremolizzo,1,2 Mario Savoiardo,3 Carlo Ferrarese1,2
    In their recent paper Chung and colleagues[1] describe 3 cases of cerebral amyloid angiopathy related inflammation (CAA-I) all confirmed by brain biopsy and review the scientific literature, proposing the criteria for probable and definite diagnosis. CAA-I is a rare and treatable encephalopathy affecting a subgroup of CAA patients, in which a predisposing condition is represented by the APOE ?4/?4 genotype in the majority of pati...
    Show More
    Conflict of Interest:
    None declared.